Skip to main content

Table 1 Clinicopathological features of 58 cases of original LCNEC

From: Pathological features, clinical presentations and prognostic factors of ovarian large cell neuroendocrine carcinoma: a case report and review of published literature

RefAgeStageSize (cm)/ LateralityAssociated componentOperationChemotherapyFollow-up
1. [10]27Ia11/leftNoneLSO/ROVBx/OM/AP/PALA/peritoneal BxTCNED10 m
2. [11]64Ia14/rightNoneTAH/BSO/OMBEPNED 9 m
3. [12]73IV9/leftNoneTAH/BSO/OM/nephrectomy/resection of brain metastasisTC → γ -knifeNED 12 m
4. [6]64IV11/rightNoneBSO/TAH/OM/peritoneal BxTC (neo adjuvant)NED 64 m
5. [13]40IIIc15/left, 7/rightNoneBSO/OM//PALA/bladder and sigmoid colon deposit excisionEPNED 6 m
6. [14]50IV25/leftNoneBSO/TAH/partialOM/APTCDOD 3 m
7. [15]35IIIc6/leftNoneTAH/BSONoAWD 3 m
8. [16]44IIIc9/rightNoneTAH/BSO/OMYesDOD 22 m
9. [17]76IIb35/eftNoneTAH/BSO/OMNoDOD post op
10. [18]77IV15/unclearNonePalliative surgeryEtoposide&carboplatinDOD 1.5 m
11. [18]58IaUnclear/leftNoneTAH/BSO/LM/OMTP → taxotereDOD 17 m
12. [18]67III13/leftNoneTAH/BSO/LM/OM/PALA/peritoneal BxTCNED 5 m
13. [19]75IV13/rightNoneTAH/BSO/LM/OM/PALA/peritoneal BxEtoposide&carboplatin →TCNED 36 m
14. [20]46III12/rightNoneTAH/BSO/OMNoDOD 4 m
15 present case70IIIc20/rightNoneTAH/BSO/OMEPNED 3 m
16. [21]71IIIb6.5/rightSerous carcinomaTAH/BSOTCNED 8 m
17. [22]47Ic11/unclearSerous adenocarcinoma & malignant brenner tumorTAH/BSO/LM/OM/AP/PALATPNED 24 m
18. [23]68IIIc7/right, 5/leftSerous adenocarcinoma with focal mucin secretionBSO/OMTC → DoxilDOD 7 m
19. [24]44Ia25/leftMucinous intraepithelial adenocarcinomaTAH/BSO/OMTCDOD 4 m
20. [2]45Ib18/rightMucinous cystadenoma (BLM) & partial intraepithelial carcinomaTAH/BSO/OMYesDOD 36 m
21. [2]58IIIb30/leftMucinous cystadenoma (BLM) & partial intraepithelial carcinomaTAH/BSO/OM/AP/LM/peritoneal BxYesDOD 8 m
22. [25]34Ic16/leftMucinous cystadenoma (BLM) & mucinous adenocarcinomaTAH/BSO/OMCPDOD 8 m
23. [3]22I21/rightMucinous tumor (BLM) & mucinous adenocarcinomaRSO/APCPDOD 3 m
24. [4]22Ia21/rightMucinous cystadenoma (BLM) & mucinous adenocarcinomaRSO/APCPDOD 3 m
25. [3]55I26/rightMucinous tumor (BLM) & intraepithelial carcinomaTAH/BSOPt-based chemotherapyNED 68 m
26. [3]55III13.5/rightMucinous tumor (BLM)TAH/BSOPt-based chemotherapyDOD 2 m
27. [26]18IV10/unclearMucinous tumor (BLM)TAH/BSO/OM/LM/PALA /prior oophorocystectomyTCDOD7m
28. [3]54I14/rightMucinous & endometrioid carcinomaTAH/BSOPt-based chemotherapyNED 66 m
29. [9]50Ia15/rightMucinous adenomaTAH/BSO/LM/OMEP → TCDOD 7 m
30. [27]65Ia16.5/leftMucinous adenomaTAH/BSO/LM/OM/APNoDOD10m
31. [28]35IcUnclearMucinous adenomaTAH/BSO/OMPt-based chemotherapyNED 120m
32. [29]68IV20/leftAdenocarcinomaTAH/BSO/LM/OMEtoposide&carboplatin, palliative radiation therapyDOD 7 m
33. [3]39IV5/rightMucinous adenocarcinomaTAH/BSOPt-based chemotherapyAWD 8 m
34. [24]73IIIc11/leftMucinous micro invasive adenocarcinomaBSO/OM/LM(Bx)/prior TAHTP DOD 8 m
35. [3]59I14/ leftAdenocarcinoma, NOSBSOPt-based chemotherapyNED 28 m
36. [30]35III15/rightMucinous cystadenoma (BLM) & mucinous adenocarcinomaTAH/BSO/OM/APYesDOD 4 m
37. [31]40Ia30/leftMucinous adenoma, cystadenoma (BLM) & mucinous adenocarcinomaTAH/BSO/LM/OM/AP/PALAYesNED 8 m
38. [32]21Ia5/rightMucinous tumor (BLM)RSOBEP → TCDOD 5 m
39. [33]70Ia16/right, unclear/leftMucinous tumor (BLM)TAH/BSO/LM/OM/APNoNED 6 m
40. [34]48I15/rightMucinous cystadenoma (BLM) & mucinous adenomaTAH/BSO/LM/OMNoNED 3 m
41. [35]36IIIc26/rightMucinous endocervical tumor (BLM)& intraepithelial carcinomaTAH/BSO/LM/OMYesNED 6 m
42. [6]65Ic15/leftEndometrioid adenocarcinoma & squamous differentiation mucinous adenocarcinomaTAH/BSO/OMTCDOD 2 m
43. [6]80IIc7/leftEndometrioid adenocarcinomaTAH/BSO/PLA/OM/APTCNED 40 m
44. [6]42IIIb13/left,
unclear/right
Endometrioid adenocarcinomaTAH/BSO/PLA/OM/PALATCNED 32 m
45. [2]77Ia15/unclearEndometrioid adenocarcinomaTAH/BSO/LM/peritoneal BxNoDOD 19 m
46. [36]33Ic11/leftEndometrioid adenocarcinomaLSO/ROVBx/partial OMCamptosarDOD 6 m
47. [3]53III14.5/leftEndometrioid adenocarcinomaTAH/BSOPt-based chemotherapyNED 37 m
48. [3]63IV14/leftEndometrioid adenocarcinomaTAH/RSOPt-based chemotherapyDOD 9 m
49. [37]49III4.6/leftEndometrioid adenocarcinomaTAH/BSO/LM/OM/peritoneal BxYesNED 4 m
50. [38]53I21/leftMucinous tumor (BLM), invasive mucinous adenocarcinoma & teratomaTAH/BSO/LM/OMEPDOD 7 m
51. [38]53IV20/leftMucinous tumor (BLM), invasive mucinous adenocarcinoma & teratomaTAH/BSO/LM/OM/peritoneal BxTCDOD 5 m
52. [3]47III14/rightAdenocarcinoma, teratoma & NOSTAH/BSOPt-based chemotherapyNED 11 m
53. [28]56IIc18/rightMucinous carcinoma & teratomaTAH/BSO/peritoneal Bx/PLANoDOD 10 m
54. [16]56Ic18/rightMucinous adenocarcinoma & teratomaTAH/BSO/LMNoDOD 10 m
55. [3]25IV5/rightTeratomaBSO/OM/APPt-based chemotherapyDOD 36 m
56. [39]69IV15/leftTeratomaLSO/thoracic BxTCDOD 6 m
57. [39].54IIIUnclearTeratomaTAH/BSO/ sigmoid resectionYesNED 12 m
58. [3]42IVUnclearBenign cyst & teratoma (contralateral ovary)TAH/BSOPt-based chemotherapyDOD 20 m